Source comparison
BPC-157 Support Long COVID Research: Comparison Table
VEGFR2 upregulation and angiogenesis Strong (multiple rodent vascular injury models) Endothelial dysfunction, microvascular damage, reduced tissue perfusion Phase 2 (ongoing, 2026 completion expected) 2–3 years to Phase 3 results NF-κB inhibition and anti-infl
This comparison does not assign a generated winner or score.
- VEGFR2 upregulation and angiogenesis
- Strong (multiple rodent vascular injury models)
- Endothelial dysfunction, microvascular damage, reduced tissue perfusion
- Phase 2 (ongoing, 2026 completion expected)
- 2–3 years to Phase 3 results
- NF-κB inhibition and anti-inflammatory effects
- Strong (validated in ulcer, tendon, and TBI models)
- Chronic systemic inflammation, neuroinflammation, persistent immune activation
- Phase 2 (neurological endpoint trials active)
- 2–4 years to clinical guidelines
- Nitric oxide pathway modulation
- Moderate (demonstrated in vascular injury, unclear dose-response in humans)
- Exercise intolerance, orthostatic dysfunction, cognitive impairment
- Preclinical to early Phase 2
- 3–5 years (requires mechanistic trial first)
- Mitochondrial biogenesis via PGC-1α
- Moderate (shown in ischemic injury models, not yet in chronic disease)
- Exercise intolerance, fatigue, post-exertional malaise
- Preclinical only
- 4–6 years (needs biomarker validation)
- Blood-brain barrier stabilization
- Moderate (TBI models, no chronic neuroinflammation data)
- Brain fog, cognitive dysfunction, autonomic dysregulation
- Phase 1 safety in CNS indications
- 5+ years (longest regulatory path)